International Scholarly Research Notices / 2012 / Article / Tab 1

Research Article

Doripenem Dosing Recommendations for Critically Ill Patients Receiving Continuous Renal Replacement Therapy

Table 1

Results of nonparametric superposition and noncompartmental analysis performed on mean data for doripenem and doripenem-M-1.

Continuous venovenous hemofiltrationContinuous venovenous hemodiafiltrationHealthy subjectsa
Day 1aSimulated steady-state (day 10)Day 1aSimulated steady-state (day 10)
500 mg
q12h
500 mg
q8h
250 mg
q8h
250 mg
q12h
500 mg
q12h
500 mg
q8h
375 mg
q12h
250 mg
q8h
250 mg
q12h
1000 mg
q8h

Doripenem
𝐶 m a x , s s (mg/L)24.129.614.913.222.526.517.913.212.044.0
A U C 𝜏 (mg h/L)97.611457.157.188.486.564.943.343.369.6
 AUC24,ss (mg h/L)N/A342.0171.3114.2N/A259.5129.8129.986.6208.8
Doripenem-M-1
𝐶 m a x , s s (mg/L)3.028.864.443.273.669.155.234.573.499.81
A U C 𝜏 (mg h/L)24.458.629.329.321.854.240.727.127.121.3
 AUC24,ss (mg h/L)N/A175.887.958.6N/A162.681.481.354.263.9

AUC24,ss: total daily area under the curve at steady state; A U C 𝜏 : area under the curve at steady state during the dosing interval 𝜏 ; 𝐶 m a x , s s : maximum plasma concentration at steady state; q8h: every 8 hours; q12h: every 12 hours.
a The day 1 500 mg q12h CRRT data and the healthy subject data are observed results from single- and multiple dose studies. All doripenem dosing regimens were a 1-hour infusion duration.